CDA | Evidence Driven
CDA | Evidence Driven

Sotrovimab for the Treatment of COVID-19

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1468-000
Effective finish date:

Question

  1. What is the clinical effectiveness of sotrovimab for the COVID-19 Omicron variant or subvariants?

Key Message

Sotrovimab may not have clinical effectiveness in treating Omicron subvariant BA.2. This finding generally aligns with the Health Canada and WHO recommendations and the findings of previously published in vitro studies against the use of sotrovimab for Omicron subvariants, except for BA.1. Given the limited number and observational, nonrandomized design of the included studies, and the absence of evidence on the clinical effectiveness of sotrovimab for outpatients with confirmed COVID-19 Omicron subvariants BA.3 to BA.5, it was difficult to draw a firm conclusion about the clinical effectiveness of sotrovimab for Omicron subvariants.

Files

Sotrovimab for the Treatment of COVID-19 View PDF
Last Updated : February 14, 2023